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Background/aim: Convalescent plasma (CP) might be an additional treatment modality in COVID-19. The aim of this study was to
compare CP-related clinical characteristics and perinatal outcomes in pregnant women with mild or moderate-severe COVID-19.
Materials and methods: This prospective cohort study included 36 pregnant women (12 mild and 24 moderate-severe), who underwent
CP therapy. The CP obtained from recently recovered donors was transfused to patients together with maximum supportive care and
antiviral agents. The groups were then compared in respect of clinical characteristics, laboratory parameters, obstetric complications,
and neonatal outcomes.
Results: Significant differences were determined between the groups in respect of systemic corticosteroids in COVID-19 treatment
(41.7%, 87.5%, p = 0.004), oxygen (O2) support (0%, 91.7%, p < 0.001), chest imaging (41.7%, 58.3%, p = 0.02), intensive care unit
admission (0%, 20.8%, p = 0.03) and length of hospitalization (5.5 versus 9.5 days, p < 0.001). The O2 saturation levels before and after
administration of CP were significantly lower in the moderate-severe COVID-19 group (p < 0.05). The O2 therapy time before and after
administration of CP and total O2 therapy time were significantly lower in the mild COVID-19 group (p < 0.05). Platelet, plateletcrit
and lymphocyte counts were significantly higher in both the mild and moderate-severe COVID-19 groups after treatment compared to
the pretreatment values (p < 0.05).
Conclusion: Although data on the results of CP treatment in pregnant women are somewhat limited, it has been suggested that early CP
treatment may be associated with improvements in laboratory and ventilatory parameters in pregnant women with mild and moderatesevere COVID-19. Nevertheless, there is a need for further, randomized controlled studies on this subject with the inclusion of greater
numbers of patients.
Key words: Clinical characteristics, convalescent plasma, COVID-19, laboratory parameters, pregnancy outcomes

1. Introduction
At the end of 2019, an outbreak of novel Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS CoV-2) spread
throughout the world resulting in the global Coronavirus
Disease 2019 (COVID-19) pandemic [1]. To date, certain
antivirals such as the malaria drug hydroxychloroquine,
remdesivir, lopinavir/ritonavir, and favipiravir have
been used in the treatment of COVID-19. For critically

ill patients, in addition to supportive therapy, such as
oxygen supply and extracorporeal membrane oxygenation
(ECMO), various therapies such as cytokine inhibitors,
stem cell therapy, and immune convalescent plasma are
still being investigated [2]. Convalescent plasma (CP) is not
available in routine practice and has not yet been licensed
by the United States Food and Drug Administration
(FDA). However, it has been made available for specific
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pathogens during periods of epidemic or pandemic. After
a minimum of 2 weeks of full recovery from COVID-19,
individuals who meet the necessary criteria can donate
CP1. This CP obtained from recovered COVID-19 patients
provides immunity based on passive antibodies. Although
neutralizing antibodies are thought to be the main active
compounds, other immune mediators in plasma may
also contribute. It is thought that CP which contains high
neutralizing antibody titers may have clinical benefits
when administered early in the course of the disease [3].
Moreover, it has been reported that CP therapy applied in
addition to antiviral therapy in severe adult COVID-19
patients can improve viremia and other clinical indices [4].
During the COVID-19 pandemic, over 100,000 units of
CP therapy have been administered as part of an expanded
access program, with an emergency use permit or during
clinical trials2.
There are studies in the literature that have reported the
successful administration of CP on a few pregnant women,
sometimes in conjunction with medical therapy (e.g.,
steroids, remdesivir, lopinavir/ritonavir, and azithromycin)
[5-7]. However, the data regarding the efficacy and safety
of CP therapy in pregnant women are insufficient3. The
research into the effects of CP on COVID-19 patients is
ongoing and is open to pregnant women who meet the
inclusion criteria4. Furthermore, there are few studies
in the literature evaluating the maternal-fetal, neonatal
results, and related laboratory parameters of pregnant
women treated with CP.
The aim of this study was to compare CP-related
clinical characteristics, obstetric complications, maternalfetal and neonatal outcomes in pregnant women with mild
or moderate-severe COVID-19, and to determine the
association of these factors with laboratory parameters.
2. Materials and methods
2. 1. Study design and case selection
This prospective cohort study included 36 pregnant
women, who were applied with CP therapy in the
Department of Obstetrics and Gynecology of Ankara City
Hospital between 28 August 2020 and 12 October 2020.
Pregnant women between the ages of 18 and 40 years were
included in the study. Approval for the study was granted by
both the Turkish Ministry of Health and the Institutional

Ethics Committee (E2-20-24). Informed consent was
obtained from all the patients. Ankara City Hospital is a
Ministry of Health tertiary reference center, which has
played a major role in the management of pandemic
patients since March 2020, when the first COVID-19 case
was recorded in Turkey [8]. For pregnant women who are
diagnosed with COVID-19, there are special protocols
with follow-up carried out by a multidisciplinary team,
comprising obstetricians, perinatologists, chest diseases
specialists, infectious diseases specialists, rheumatologists,
anesthesiologists, and neonatologists. Although Ankara
City Hospital is a pandemic center, the follow-up of all
pregnant women continues, resulting in approximately
1100 deliveries per month [9].
The diagnosis of COVID-19 was made from the realtime polymerase chain reaction (RT-PCR) assay applied
to nasopharyngeal and oropharyngeal specimens [10].
National guidelines were followed for the classification
of the severity of disease and management of COVID-19
patients5. The COVID-19 convalescent plasma (CP)
obtained from recently recovered donors was transfused to
patients at a dose of 200 mL high neutralizing titers (>1/80)
together with maximum supportive care and antiviral
agents. CP therapy was not administered to patients with
immunoglobulin-A (IgA) deficiency3. The CP administered
to each patient came from a single batch.
2. 2. Study parameters
The pregnant women undergoing CP treatment in this study
were classified into two groups as mild and moderate-severe.
The groups were then compared in respect of demographic
features, clinical characteristics, obstetric complications, and
neonatal outcomes. Maternal age, body-mass index (BMI)
(kg/m2), gravidity, parity, previous miscarriage, comorbid
conditions, gestational age at diagnosis, pregnancy status,
route of delivery, indications for cesarean delivery, obstetric
complications, tocolytic therapy, antenatal corticosteroid
therapy for fetal maturation, COVID-19 treatment,
oxygen (O2) support, chest imaging, intensive care unit
(ICU) admission, length of hospitalization, birth weight,
gestational age at birth, 1 and 5-min Apgar scores, and
neonatal intensive care unit (NICU) admission rates were
compared between the groups.
CP-related clinical characteristics such as the day of
plasma administration, allergic reaction and side-effects

The United States Food and Drug Administration (FDA) (2021). Website: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/
updated-information-blood-establishments-regarding-covid-19-pandemic-and-blood-donation [accessed on 19 January 2021]
1

2

Expanded Access Program for Convalescent Plasma (2021). Website: https://www.uscovidplasma.org [accessed on 28 February 2021]

Turkish Ministry of Health, COVID-19 Immune (Convalescent) Plasma Supply and Clinical Use Guide (2020). Website: https://shgm.saglik.gov.tr/
Eklenti/39179/0/covid-19-immun-konvalesan-plazma-tedarik-ve-klinik-kullanim-rehberipdf.pdf [accessed on 30 October 2020]
3

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients with Pneumonia Caused by SARS-CoV-2 (2021). Website: https://
clinicaltrials.gov/ct2/show/NCT04397757 [accessed on 22 January 2021]
4

Turkish Ministry of Health, General Directorate of Public Health, COVID-19 (SARS-CoV-2 infection) Guideline, Scientific Committee Report (2020).
Website: https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html [accessed on 3 September 2020]
5
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after administration of plasma, O2 saturation and O2
therapy time before and after administration of plasma,
total O2 therapy time, body temperature, heart rate,
systolic blood pressure, and diastolic blood pressure
before and after administration of plasma were compared
between the pregnant women with mild and moderatesevere COVID-19.
The CP-related laboratory parameters of initial white
blood cell (WBC), neutrophil, and lymphocyte counts,
neutrophil-lymphocyte ratio (NLR), C-reactive protein
(CRP), interleukin 6 (IL-6), procalcitonin, ferritin, platelet
(PLT), plateletcrit (PCT), alanine transferase (ALT),
aspartate transferase (AST), D-dimer, fibrinogen, and
immunoglobulin A (IgA) levels were compared before and
after administration of plasma between pregnant women
with mild and moderate-severe COVID-19.
The laboratory parameters and clinical characteristics
such as fibrinogen, ferritin, procalcitonin, CRP, PCT,
WBC, PLT, neutrophil, lymphocyte, NLR, AST, ALT, IL6, D-dimer, O2 saturation, body temperature, heart rate,
systolic and diastolic blood pressure before and after the
administration of CP were compared between the groups
of pregnant women with mild and moderate-severe
COVID-19.
2. 3. Statistical analysis
Data obtained in the study were analyzed statistically
using SPSS vn. 26.0 software (Statistical Package for the
Social Sciences for Windows, IBM Corpn, Armonk, NY,
USA). Descriptive statistics were presented as median
and interquartile range values as the variables did not
show normal distribution. Median values were compared
between groups using the Mann-Whitney U-test.
Categorical variables were reported as number (n) and
percentage (%). The chi-square test was applied to the
comparisons between groups of categorical variables. The
Wilcoxon signed-rank test was used in the comparison of
dependent groups. The level of statistical significance in all
the analyses was accepted as a two-tailed value of p < 0.05.
3. Results
CP treatment was administered to 12 (33.3%) pregnant
women with mild COVID-19 and to 24 (66.6%) pregnant
women with moderate-severe COVID-19. CP therapy
is more preferred in the moderate-severe group in
COVID-19. The comparisons between the mild and
moderate-severe groups in respect of demographic
features, clinical characteristics, obstetric complications
and neonatal outcomes are shown in Table 1. Significant
differences were determined between the groups in respect
of systemic corticosteroids in COVID-19 treatment (41.7%,
87.5%, p = 0.004), O2 support (0%, 91.7%, p < 0.001),
chest imaging (41.7%, 58.3%, p = 0.02), ICU admission
(0%, 20.8%, p = 0.03), and length of hospitalization (5.5
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versus 9.5, p < 0.001, respectively). Other variables were
similar in the two groups.
Comparisons between pregnant women with mild
and moderate-severe COVID-19 in respect of CP-related
clinical characteristics are shown in Table 2. The two groups
were comparable in terms of the plasma administration
day, allergic reaction and side-effects, body temperature,
heart rate, and systolic and diastolic blood pressure values
before and after administration of plasma were similar
in both groups. The O2 saturation levels before and after
administration of plasma were significantly lower in the
moderate-severe COVID-19 group (p < 0.05). The O2
therapy time before and after administration of plasma
and total O2 therapy time were significantly lower in the
mild COVID-19 group (p < 0.05).
The comparisons of CP-related laboratory parameters
between the mild and moderate-severe COVID-19 groups
are shown in Table 3. In respect of initial WBC, neutrophil,
lymphocyte counts, NLR, CRP, IL-6, procalcitonin, ferritin,
PLT, PCT, ALT, AST, D-dimer, fibrinogen, and IgA levels,
the two groups were comparable, and no difference was
determined between the groups after CP administration
in respect of lymphocyte, NLR, CRP, IL-6, procalcitonin,
ferritin, PLT, PCT, ALT, AST, D-dimer and fibrinogen
levels. The WBC and neutrophil levels were found to be
significantly higher in the moderate-severe COVID-19
group (p = 0.03).
The comparisons of laboratory parameters and
clinical characteristics before and after CP administration
in pregnant women with mild and moderate-severe
COVID-19 are shown in Table 4. The sampling times for
the parameters were defined as the day of hospitalization
(before) and the first day after CP treatment (after). No
differences were determined between the groups in respect
of ferritin, neutrophil counts, NLR, IL-6, and diastolic
blood pressure levels. In the moderate-severe COVID-19
group, fibrinogen, CRP, and body temperature values were
significantly lower than in the mild COVID-19 group (p
< 0.05). WBC, AST, ALT, and O2 saturation levels were
determined to be statistically significantly higher in
pregnant women with moderate-severe COVID-19 (p
< 0.05). Procalcitonin, D-dimer, heart rate, and systolic
blood pressure levels were statistically significantly lower
in the mild COVID-19 group compared to the pregnant
women with moderate-severe COVID-19 (p < 0.05). PCT,
PLT, and lymphocyte counts were significantly higher in
both the mild and moderate-severe COVID-19 groups
after treatment compared to the pretreatment values (p <
0.05).
4. Discussion
The main findings of the present study indicated that
convalescent plasma might be an additional treatment
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Table 1. Comparison of demographic features, clinical characteristics, obstetric complications, and neonatal outcomes between pregnant
women with mild and moderate-severe COVID-19.
Mild COVID-19 group Moderate-severe COVID-19
(n = 12)
group (n = 24)

p value

Maternal age (years) (median, IQR)a

27.5 (10)

29.5 (10)

0.40

BMI (kg/m ) (median, IQR)

24.51 (3)

25.71 (4)

0.12

Gravidity (median, IQR)a

2 (3)

2 (1)

0.72

Parity (median, IQR)

1 (1)

1 (2)

0.79

Living child (median, IQR)a

1 (1)

1 (2)

0.45

Previous miscarriage (median, IQR)

0 (0)

0 (0)

0.93

Comorbidity (n, %)

5 (41.6%)

5 (20.8%)

0.77

Variables

2

a

a

a

b

Comorbidity type (n, %)b

0.12

Hypothyroidism (n, %)

2 (16.6%)

0 (0%)

Thrombocytopenia (n, %)

1 (8.3%)

0 (0%)

Asthma (n, %)

0 (0%)

1 (4.1%)

Hypertension (n, %)

0 (0%)

2 (8.3%)

Maternal cardiac disease (n, %)

0 (0%)

1 (4.1%)

Diabetes mellitus type 2 (n, %)

0 (0%)

1 (4.1%)

Maternal varicose veins (n, %)

0 (0%)

1 (4.1%)

Hemolytic anemia

1 (8.3%)

0 (0%)

Celiac disease

1 (8.3%)

0 (0%)

Hydatid cyst of the liver

1 (8.3%)

0 (0%)

27.5 (8.75)

26.5 (17.5)

Gestational age (weeks) (median, IQR)

a

Trimesters at diagnosis

0.32
0.38

First trimester

0 (0%)

2 (8.3%)

Second trimester

7 (58.3%)

11 (45.8%)

Third trimester

5 (41.7%)

11 (45.8%)

Pregnancy conceived by assisted reproductive technology (n, %)

0 (0%)

1 (2.7%)

Twin pregnancy (n, %)b

0 (0%)

3 (8.3%)

b

Pregnancy status (n,%)

0.34

b

On-going pregnancy (n, %)

6 (50%)

12 (50%)

Delivered (n, %)

6 (50%)

12 (50%)

Route of delivery (vaginal) (n, %)

3 (25%)

2 (8.3%)

Route of delivery (cesarean section) (n, %)b

3 (25%)

10 (41.7%)

b

Indications for cesarean delivery (n, %)

0.12

b

Maternal COVID-19 pneumonia (n, %)

0 (0%)

2 (20%)

Previous cesarean delivery

4 (100%)

3 (30%)

Nonreassuring fetal status

0 (0%)

2 (20%)

Multiple pregnancy

0 (0%)

2 (20%)

Maternal sinus vein thrombosis

0 (0%)

1 (10%)

Obstetric complication (n, %)

1 (8.3%)

6 (25%)

b

b

Obstetric complication type (n, %)b

0.08
0.39

GHT (n, %)

0 (0%)

1 (4.1%)

HG (n, %)

0 (0%)

1 (4.1%)
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Table 1. (Continued).
Elevated liver enzymes (n, %)

0 (0%)

3 (12.5%)

Hypokalemia (n, %)

0 (0%)

3 (12.5%)

Tocolytic therapy (n, %)b

0 (0%)

1 (4.1%)

0.36

Antenatal corticosteroid therapy for fetal maturation (n, %)

1 (8.3%)

2 (8.3%)

0.71

COVID-19 treatment (n, %)b

12 (100%)

24 (100%)

>0.05

Hydroxychloroquine (n, %)b

3 (25%)

7 (29.1%)

0.79

Lopinavir/Ritonavir (n, %)

4 (33.3%)

13 (54.1%)

0.23

Azithromycin (n, %)

0 (0%)

1 (4.1%)

0.36

Favipiravir (n, %)b

0 (0%)

3 (12.5%)

0.10

Vitamin C (n, %)

0 (0%)

1 (4.1%)

0.36

Low molecular weight heparin (n, %)b

11 (91.6%)

23 (95.8%)

0.60

Systemic corticosteroids (n, %)

5 (41.7%)

21 (87.5%)

0.004

Anakinra (n, %)b

1 (8.3%)

8 (33.3%)

0.08

Tocilizumab (n, %)

0 (0%)

1 (4.1%)

0.36

Remdesivir (n, %)b

0 (0%)

1 (4.1%)

0.37

Colchicine (n, %)

1 (8.3%)

1 (4.1%)

0.59

O2 support (n, %)b

0 (0%)

22 (91.7%)

<0.001

Nasal oxygen (n, %)b

0 (0%)

17 (70.8%)

Reservoir mask (n, %)b

0 (0%)

2 (8.3%)

High-flow (n, %)

0 (0%)

3 (12.5%)

Intubation (n, %)b

0 (0%)

1 (4.1%)

Chest imaging (n, %)

5 (41.7%)

14 (58.3%)

0.02

Chest graphy (n, %)b

4 (36.4%)

12 (50%)

0.45

CT scan (n, %)

1 (8.3%)

4 (16.7)

0.47

ICU admission (n, %)b

0 (0%)

5 (20.8%)

0.03

5.5 (4)

9.5 (5.5)

<0.001

3070 (1120)

2690 (1170)

0.13

Gestational age at birth (weeks) (median, IQR)

37 (4)

37 (6)

0.40

a

1 min Apgar score (median, IQR)

8 (1)

7 (2)

0.09

5 min Apgar score (median, IQR)a

9 (1)

8 (1)

0.20

NICU admission (n,%)

0 (0%)

1 (8.3%)

0.33

b

COVID-19 treatment type (n, % b
)

b

b

b

b

b

b

O2 support type (n, %)

b

b

b

b

Length of hospitalization (days) (median, IQR)

a

Birth weight (gr) (median, IQR)a
a

b

BMI: Body-mass index, COVID-19: Coronavirus disease 2019, CT: Computed tomography, GHT: Gestational hypertension, HG:
Hyperemesis gravidarum, ICU: Intensive care unit, IQR: Interquartile range, NICU: Neonatal intensive care unit, O2: Oxygen
a
Statistical analysis was performed using the Mann-Whitney U test
b
Statistical analysis was performed using the chi-square test

modality in selected pregnant women. Potentially
favourable effects were seen on the inflammation
parameters and the necessity for oxygen therapy in
both mild and severe cases. As knowledge is still limited
on the efficacy and safety of convalescent plasma for
pregnant women with COVID-19, these findings may
be of guidance in future studies. Although the relatively
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low number of cases and the absence of a control group
due to the unique characteristics of the study population
limit the interpretation of the results, this study revealed
favorable outcomes of the use of CP in pregnant women
with COVID-19.
The World Health Organization (WHO) and the
US Food and Drug Administration (FDA) reported
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Table 2. Comparison of convalescent plasma-related clinical characteristics between pregnant women with mild and moderate-severe
COVID-19.

Variables

Moderate-severe
Mild COVID-19
COVID-19
group (n = 12)
group (n = 24)

p value

Administration day of plasma (median, IQR)a

2.5 (2)

4 (2.75)

0.17

Allergic reaction after administration of plasma (n, %)b

1 (8.3%)

0 (0%)

0.33

Side-effects after administration of plasma (n, %)

3 (25%)

7 (29%)

0.40

Fever (n, %)

2 (16.7%)

2 (8.3%)

Lymphopenia (n, %)

1 (8.3%)

2 (8.3%)

Fever and lymphopenia (n, %)

0 (0%)

3 (12.5%)

O2 saturation before administration of plasma (%) (median, IQR)a

98 (2)

92 (6)

<0.001

O2 saturation after administration of plasma (%) (median, IQR)

97 (1)

94.5 (3)

0.005

O2 therapy time before administration of plasma (days) (median, IQR)a

0 (0)

2 (4)

0.01

O2 therapy time after administration of plasma (days) (median, IQR)

0 (1.5)

4 (5.5)

<0.001

Total O2 therapy time (days) (median, IQR)a

0 (2.2)

7 (4.7)

<0.001

Body temperature before administration of plasma (°C) (median, IQR)

37.5 (1.7)

37.4 (1.4)

0.67

Body temperature after administration of plasma (°C) (median, IQR)a

36.7 (0.7)

36.6 (1.4)

0.54

110 (0.2)

100 (0.2)

0.67

89 (9.5)

88 (27.2)

0.50

Systolic blood pressure before administration of plasma (mmHg) (median, IQR)

117 (18.7)

110 (14)

0.31

Systolic blood pressure after administration of plasma (mmHg) (median, IQR)

102.5 (11.5)

b

a

a

a

Heart rate before administration of plasma (per minute) (median, IQR)

a

Heart rate after administration of plasma (per minute) (median, IQR)a
a

109.5 (15.5)

0.11

Diastolic blood pressure before administration of plasma (mmHg) (median, IQR)a 62.5 (15.7)

70 (11.2)

0.83

Diastolic blood pressure after administration of plasma (mmHg) (median, IQR)

63 (13.2)

0.68

a

a

65 (10)

COVID-19: Coronavirus disease 2019, IQR: Interquartile range, O2: Oxygen
a
Statistical analysis was performed using the Mann-Whitney U test
b
Statistical analysis was performed using the chi-square test

that convalescent plasma (CP) was used during the
H1N1 influenza virus epidemic in 2009-2010, and in
the outbreaks of SARS-CoV-1 in 2003, and Middle East
Respiratory Syndrome (MERS-CoV) in 20126. It has also
been reported that the use of CP containing antibodies
against COVID-19 may be effective against this latest
infection [11]. The IgG antibodies in particular, which
are specific to SARS-CoV-2 and are passively transferred
by the transfused plasma, are thought to have a role in
neutralising viral particles and activating the complement
system, thereby allowing elimination of the virus [12]. In
a study of 10 patients with severe COVID-19, Duan et al.
administered a single dose of 200 mL CP from recently
healed donors with neutralizing antibody titres >1/640 in
addition to standard therapy. The results demonstrated
that within 3 days, the clinical symptoms significantly
improved with increased oxyhemoglobin saturation, and

various parameters showed an improving trend, including
increased lymphocytes and decreased CRP. CP treatment
has been reported to be well tolerated and may have the
potential to improve clinical outcomes by neutralizing
viremia in patients with severe COVID-19 [13]. The results
of the current study showed that CRP and fibrinogen
levels decreased, and O2 saturation and lymphocyte levels
increased after CP treatment in the moderate-severe
COVID-19 group.
For individuals who have not been previously exposed
to or vaccinated with the viral pathogen, the development
of the response to antibodies can take up to two to three
weeks [14]. Therefore, the provision of antibodies has the
positive potential of shortening the duration of the disease
and preventing serious life-threatening complications [15].
However, it has been stated that it may be more appropriate
to administer CP to patients with a severe disease course in

The World Health Organization (WHO), Guidance on Maintaining a Safe and Adequate Blood Supply During the COVID-19 Pandemic and on the
Collection of COVID-19 Convalescent Plasma: Interim Guidance (2020). Website: https://apps.who.int/iris/handle/10665/333182 [accessed on 10 July
2020]
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Table 3. Comparison of convalescent plasma-related laboratory parameters between pregnant women with mild and moderate-severe
COVID-19.
Mild COVID-19 group Moderate-severe COVID-19
(n = 12)
group (n = 24)

p value

6430 (3315)

6630 (3773)

0.86

WBC after administration of plasma (10 /mL) (median, IQR)

6135 (4632)

8500 (3522)

0.03

Neutrophil (103/mL) (median, IQR)a

5025 (2797)

4820 (3345)

0.86

Neutrophil after administration of plasma (10 /mL) (median, IQR)

4615 (3882)

6640 (4057)

0.03

Lymphocyte (103/mL) (median, IQR)a

775 (222)

800 (442)

0.63

Lymphocyte after administration of plasma (10 /mL) (median, IQR)

955 (285)

1150 (547)

0.68

NLR (%) (median, IQR)a

6.98 (4)

5.6 (4.9)

0.56

NLR after administration of plasma (%) (median, IQR)

4.29 (3.8)

5.91 (6.71)

0.31

CRP (mg/dL) (median, IQR)a

31.1 (36.6)

45.2 (71.1)

0.50

CRP after administration of plasma (mg/dL) (median, IQR)

11.2 (44.4)

21.6 (47.1)

0.58

IL-6 (pg/mL) (median, IQR)a

11.5 (10.3)

15.3 (13.3)

0.16

IL-6 after administration of plasma (pg/mL) (median, IQR)

6.58 (8.4)

5.58 (20.4)

0.94

Procalcitonin (ng/mL) (median, IQR)a

0.03 (0.06)

0.03 (0.07)

0.35

Procalcitonin after administration of plasma (ng/mL) (median, IQR)

0.03 (0.07)

0.03 (0.08)

0.86

Ferritin (ng/mL) (median, IQR)

48 (79)

35.5 (143)

0.80

Ferritin after administration of plasma (ng/mL) (median, IQR)a

45.5 (107.7)

58.5 (119)

0.38

PLT (10 /mL) (median, IQR)

172 (60.2)

189 (38.7)

0.51

PLT after administration of plasma (103/mL) (median, IQR)a

226 (180.7)

266 (153.5)

0.26

PCT before administration of plasma (%) (median, IQR)

0.15 (0.07)

0.18 (0.05)

0.62

PCT after administration of plasma (%) (median, IQR)a

0.21 (0.14)

0.23 (0.13)

0.31

ALT (U/L) (median, IQR)

21 (10)

16 (19)

0.62

ALT after administration of plasma (U/L) (median, IQR)a

23.5 (32.2)

29 (87.7)

0.21

AST (U/L) (median, IQR)

29 (31)

28 (26)

0.44

AST after administration of plasma (U/L) (median, IQR)a

38 (33.7)

35.5 (69.2)

0.67

2.1 (1.9)

2.4 (3)

0.89

D-dimer after administration of plasma (mcg/mL) (median, IQR)

1.7 (0.9)

2.15 (3.48)

0.27

Fibrinogen (g/L) (median, IQR)a

4.4 (1.2)

4.4 (1.2)

0.51

Fibrinogen after administration of plasma (g/L) (median, IQR)

4.59 (1.06)

3.98 (1.72)

0.16

IgA before administration of plasma (mg/dL) (median, IQR)a

1.84 (1.42)

1.48 (0.98)

0.38

Variables
WBC (103/mL) (median, IQR)a
3

a

3

a

3

a

a

a

a

a

a

3

a

a

a

a

D-dimer (mcg/mL) (median, IQR)

a
a

a

ALT: Alanine transferase, AST: Aspartate transferase, COVID-19: Coronavirus disease 2019, CRP: C-reactive protein, IL-6: Interleukin
6, IgA: Immunoglobulin A, IQR: Interquartile range, PCT: Plateletcrit, PLT: Platelet count, NLR: Neutrophil to lymphocyte ratio, WBC:
White blood cell
a
Statistical analysis was performed using the Mann-Whitney U test

the early stages of clinical admission, before the need for
intensive care develops [12, 16–18]. When there is critical
infection due to organ damage or massive inflammation,
the benefit of CP on these complications remains uncertain
[19]. During the recovery period of COVID-19, the IgM
anti-Spike protein (S) and anti-Nucleocapsid protein (N)
have been reported to start to appear within about a week,
and continue to increase for two weeks, while IgG has been
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observed to increase after a few days (typically during the
third week). This change has been seen to occur more
rapidly in nonintensive care unit patients (ICU) compared
to ICU patients [20].
Increased survival has been reported in randomized
studies using high titer CP in the early stages of the disease. In
a previous, randomized, double-blind, placebo-controlled
study of 160 patients aged >65 years, the administration of

EROL et al. / Turk J Med Sci
Table 4. Comparison of laboratory parameters and clinical characteristics before and after the administration of convalescent plasma
between pregnant women with mild and moderate-severe COVID-19.
Mild
COVID-19 group

Moderate-severe
COVID-19 group

Fibrinogen after/before administration of plasma (z) (p value)a

–0.41 (0.67)

–2.13 (0.03)

Ferritin after/before administration of plasma (z) (p value)

–1.6 (0.11)

–0.92 (0.35)

Procalcitonin after/before administration of plasma (z) (p value)a

–2.05 (0.04)

–0.79 (0.43)

CRP after/before administration of plasma (z) (p value)

–1.80 (0.07)

–2.14 (0.03)

PCT after/before administration of plasma (z) (p value)a

–2.76 (0.006)

–3.91 (<0.001)

WBC after/before administration of plasma (z) (p value)

–0.23 (0.81)

–2.38 (0.01)

PLT after/before administration of plasma (z) (p value)a

–2.51 (0.01)

–3.92 (<0.001)

Variables

a

a

a

Neutrophil after/before administration of plasma (z) (p value)

–0.23 (0.81)

–1.9 (0.05)

Lymphocyte after/before administration of plasma (z) (p value)a

–2.61 (0.009)

–2.61 (0.009)

a

NLR after/before administration of plasma (z) (p value)

–1.41 (0.15)

–0.54 (0.58)

AST after/before administration of plasma (z) (p value)a

–0.47 (0.63)

–2.93 (0.003)

a

ALT after/before administration of plasma (z) (p value)

–1.41 (0.15)

–3.45 (0.001)

a

IL-6 after/before administration of plasma (z) (p value)

–1.12 (0.26)

–0.85 (0.39)

D-dimer after/before administration of plasma (z) (p value)a

–2.58 (0.01)

–1.07 (0.28)

O2 saturation after/before administration of plasma (z) (p value)

–1.89 (0.05)

–2.96 (0.003)

Body temperature after/before administration of plasma (z) (p value)a

–0.84 (0.39)

–2.47 (0.01)

Heart rate after/before administration of plasma (z) (p value)

–2.50 (0.01)

–1.75 (0.08)

Systolic blood pressure after/before administration of plasma (z) (p value)a

–2.55 (0.01)

–0.16 (0.87)

–0.14 (0.88)

–1.61 (0.10)

a

a

a

Diastolic blood pressure after/before administration of plasma (z) (p value)

a

ALT: Alanine transferase, AST: Aspartate transferase, COVID-19: Coronavirus disease 2019, CRP: C-reactive protein, IL-6: Interleukin
6, O2: Oxygen, PCT: Plateletcrit, PLT: Platelet count, NLR: Neutrophil to lymphocyte ratio, WBC: White blood cell
a

Statistical analysis was performed using the Wilcoxon signed-rank test

CP within 72 h of the onset of symptoms (mild disease) was
seen to result in a lower probability of progression to severe
disease (respiratory rate ≥ 30/min, oxygen saturation
< 93%), and a lower probability of mortality [16]. In the
current study, CP was transfused to patients in both the
mild and moderate-severe groups in the early period. In a
randomized study conducted on 81 hospitalized patients,
the requirement for high-flow oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO), and the mortality rates on days 15–29 were
reported to be lower for patients treated with CP (0% vs.
14%, 0% vs. 9%, respectively) [21]. In an observational
study including more than 35,000 patients treated with
CP in the USA, lower mortality rates (7-day mortality:
9% vs. 12%) were reported in patients administered with
CP within the first 3 days of presentation [22]. Similarly,
in another observational study of 351 patients treated with
CP, mortality rates were lower in patients who were not
intubated and received CP within 72 h of hospitalization
(60-day mortality rate: 4% vs. 12.3%) [23].

In studies, which did not include sufficient antibody
titer (<1/80), or in which CP treatment was administered
in the late stage of the disease, no positive benefits could
be seen on survival and disease progression. This was
attributed to the onset of an endogenous self-antibody
response within 8–10 days of infection and disease
progression, in addition to the inflammatory response
rather than the virus itself [24]. CP treatment appears to
be applicable without delay and without disrupting other
available therapies, including antiviral agents. Moreover,
as there is expected to be lower efficacy of CP therapy in
mutant SARS-CoV-2 variants in the receptor binding sites,
there is a need for further studies [25].
Although the optimal dose of CP is still unknown,
institutional or clinical trial protocols should be followed.
In the current study, early and single-dose CP therapy was
administered as described in literature3. It is also important
to know that plasma transfusions may be associated with
transfusion reactions such as allergic reactions, acute
lung injury due to transfusion, and circulatory overload
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[26,27]. Approximately 20,000 CP replacements have been
reported to have been concluded with low rates of negative
side-effects such as transfusion reactions, thromboembolic
complications, and cardiac events (<1%, 1%, and 3%,
respectively) [28]. In the current study, no serious negative
side-effects were observed related to the CP transfusion.
Previous studies have reported the successful
administration of CP in a limited number of pregnant
women, sometimes in combination with medical
therapy (e.g., steroids, remdesivir, lopinavir/ritonavir,
azithromycin). In a case report of a 24-week pregnant
patient with COVID-19 pneumonia followed up in ICU,
Grisolia et al. administered 2 doses of 300 mL CP on the
7th and 12th days after the onset of symptoms, together
with medical treatment and reported rapid normalization
in body temperature and SPO2, decreased CRP and
improved clinical status [29]. In another case of a 35-week
pregnant patient, Zhang et al. administered 300 mL of CP
on day 19 in addition to medical treatment due to severe
acute respiratory distress syndrome (ARDS), multiple
organ dysfunction syndrome (MODS), and septic shock
after COVID-19. It was concluded that CP could be a
potential treatment option for critically ill COVID-19
patients [30]. Anderson et al. administered CP to a 22week pregnant COVID-19 patient with comorbid type
2 diabetes mellitus (DM), asthma, and class 3 obesity, in
addition to the medical treatment as ARDS developed 24
h after hospital admission and the patient required ICU.
It was emphasized in that report that the remdesivir
treatment may shorten the extubation period, and
reduce mortality in patients with COVID-19 in need of
mechanical ventilation [7]. In the current study, patients
had similar comorbidities, with a higher incidence in
the moderate-severe group. It has been reported that
attentive corticosteroid therapy combined with the
transfusion of CP may lead to positive results in pregnant
women with ARDS in terms of suppressing viremia and
cytokine storm [6]. A 27-week intubated pregnant patient,
who was treated with 2 doses of CP on the 4th and 5th
days of hospitalization, was discharged on the 14th day.
This highlighted that the administration of CP could
be associated with maternal survival, and it could be a
safe alternative for pregnant women with a seronegative
condition, rapid deterioration in respiratory functions,
and fetal distress [5]. In accordance with the literature,
increased nonreassuring fetal status, cesarean section,
oxygen support and ICU admission rates were observed in
the moderate-severe group in the current study.
There are few studies in literature that have evaluated
the effects of CP on clinical characteristics and laboratory
parameters. In a study of 25 patients with severe and/or
life-threatening COVID-19, Salazar et al. stated that with
CP administered at mean 6 days, there was a decrease in
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CRP and an increase in WBC on days 0, 7, and 14 days
after the CP administration, and concluded that CP was
a safe treatment option [31]. Khamis et al. reported that
laboratory and ventilatory parameters improved after
therapeutic plasma exchange (TPE) in 11 patients with
severe COVID-19 [32]. In the current study, a decrease in
procalcitonin and D-dimer levels after CP were determined
in the mild group, a decrease in fibrinogen and CRP levels
in the moderate-severe group, and an increase in WBC and
O2 saturation, and in PCT, PLT and lymphocyte counts in
both groups, consistent with previous findings in literature.
The changes in WBC, AST, ALT, and O2 saturation after CP
administration were determined to be statistically higher
in the pregnant women in the moderate-severe group,
suggesting that inflammatory processes may have increased
in the moderate-severe group. However, procalcitonin,
neutrophil, and IL-6 values were not statistically different
in the moderate-severe group. In a study by Xia et al.,
it was reported that in the group with good response to
CP treatment, the lymphocyte percentage was high, and
neutrophil percentage and CRP were low, whereas in
the nonresponsive group, lactate dehydrogenase (LDH),
B-type natriuretic peptide, urea nitrogen, procalcitonin
and glucose levels were found to be higher. Abnormal
metabolic functions and a strong inflammatory response
were associated with a low response to CP treatment [33].
Strong aspects of this study can be considered to be the
prospective design with the inclusion of pregnant women
compared in mild and moderate-severe groups according
to several parameters. However, the study also had
limitations, primarily that it was an observational study,
there was no control group receiving a standard treatment
regimen, and a limited number of pregnant women with
COVID-19 were included. Secondly, there were no data
on viral load and/or neutralizing Ab titres (in pregnant
mothers and newborns).
5. Conclusion
Although data on the results of CP treatment in pregnant
women are somewhat limited, the results of this study
suggest that early CP treatment may be associated with
improvements in laboratory and ventilatory parameters
in pregnant women with mild and moderate-severe
COVID-19. Nevertheless, there is a need for further,
randomized controlled studies on this subject with the
inclusion of greater numbers of patients.
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